Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-676 with Pembrolizumab and Radiation in Advanced Solid Tumors
NCT04879849Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dazostinag in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous cell carcinoma of the head and neck (HNSCC), sponsored by Takeda. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events at 32 months, Number of Participants With Dose-limiting Toxicities at 21 days and 3 more. Started Sep 2021; status: completed.
02
Drugs
dazostinag
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04879849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879849.